

July 18, 2025

Company name: SanBio Co., Ltd.
 Representative: Keita Mori, Representative Director and President
 (TSE Growth Code: 4592)
 Contact: Yoshihiro Kakutani, Corporate Officer of Management Administration
 (TEL. +81-3-6264-3481)

Notice on Conclusion of Committed Credit Line Agreement with MUFG Bank, Ltd.

SanBio Company Limited (hereafter, “the Company”) hereby announces that it has entered into a new committed credit line agreement with MUFG Bank, Ltd. on July 18th today.

The company is aiming to obtain approval for a partial change application of AKUUGO[®] Suspension for Intracranial Implantation (AKUUGO[®]) that had obtained conditional and time-limited approval in July 2024. The funds secured from the new agreement will be allocated to the marketing as working capital for the commercialization of AKUUGO[®].

Agreement with MUFG Bank, Ltd. dated today, June 9, 2025

Loan type	Total committed amount (of which, used credit)	Agreement date	Expiration date	Remarks
Committed credit line	1.0 billion yen (- million yen)	Jul. 2025	Feb. 2027	Expenses related to the commercialization of AKUUGO [®]

The status of committed credit line agreement at present is as follows.

Bank Name	Total committed amount (of which, used credit)	Agreement date	Expiration date	Remarks
MUFG Bank, Ltd.	1.0 billion yen (- million yen)	Jul. 2025	Feb. 2027	Expenses related to the commercialization of AKUUGO [®]
Mizuho Bank, Ltd.	1.0 billion yen (- million yen)	Jun. 2025	Nov. 2026	The establishment of manufacture, distribution, and marketing infrastructure for AKUUGO [®]
Resona Bank, Limited	1.0 billion yen (- million yen)	Mar. 2025	Mar. 2027	The establishment of manufacture, distribution, and marketing infrastructure for AKUUGO [®] after obtaining approval for partial change

The new committed credit line agreement is expected to have only a minor impact on the Company Group’s consolidated earnings performance for the fiscal year ending January 2026.